Clinical Trials Browser

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Hematologic Neoplasms, Triple Negative Breast Neoplasms

Clinical Trials

Pembrolizumab in Preventing Lung Cancer in Patients With Stage I-II Non-Small Cell Lung Cancer or High-Risk Pulmonary Nodules, the IMPRINT-Lung Study

Phase Ib of L-NMMA and Pembrolizumab

SPRINT

Nivolumab With or Without Ipilimumab or Chemotherapy in Treating Patients With Previously Untreated Stage I-IIIA Non-small Cell Lung Cancer

A Multiple Antigen Vaccine (STEMVAC) for the Treatment of Patients With Stage IV Non-Small Cell Lung Cancer

Phase I/II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Non Small Cell Lung Cancer

Osimertinib in Treating Participants With Stage I-IIIA EGFR-mutant Non-small Cell Lung Cancer Before Surgery

Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases

TOP 1501

Priming Immunotherapy in Advanced Disease With Radiation

Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases

iSMART

Understanding the Post-Surgical Non-Small Cell Lung Cancer Patient's Symptom Experience

Nivolumab Plus Cisplatin/Pemetrexed or Cisplatin/Gemcitabine as Induction in Resectable Non-Small Cell Lung Cancer

MK-3475 and Gemcitabine in Non-Small Cell Lung Cancer (NSCLC)

ALT-803 Plus Nivolumab in Patients With Pretreated, Advanced or Metastatic Non-Small Cell Lung Cancer

Rucaparib and Pembrolizumab for Maintenance Therapy in Stage IV Non-Squamous Non-Small Cell Lung Cancer

Intratumoral Cisplatin for Resectable NSCLC

Use of High Dose Radiation Followed by Chemotherapy and Radiation to Treat Locally Advanced NSCLC

Atezolizumab and Varlilumab in Combination With Radiation Therapy for NSCLC

PRIMING

UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade

Tiragolumab and Atezolizumab in Patients With Non-squamous Non-small Cell Lung Cancer (NSCLC) and Untreated Brain Metastases

Pembrolizumab + Imprime PGG for Metastatic Non-small Cell Lung Cancer After Progression on First-Line Therapy: Big Ten Cancer Research Consortium BTCRC-LUN15-017

Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC)

Biomarkers of Response to Ipilimumab and Nivolumab in First-line NSCLC

Pembro and Vorinostat for Patients With Stage IV Non-small Cell Lung Cancer (NSCLC)

A Trial of Integrating SBRT With Targeted Therapy in Stage IV Oncogene-driven NSCLC

Pembrolizumab, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Stage II-IIIB Non-Small Cell Lung Cancer

Tarlox and Sotorasib in Patients With KRAS G12C Mutations

TELMA

NA_00092076

Platinum Doublet Chemotherapy and Proton Beam Radiation Therapy in Treating Patients With Stage II-III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery

Maintenance Chemotherapy With or Without Local Consolidative Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer

TG4010 and Nivolumab in Patients With Lung Cancer

Radical RADiotherapy and Immunotherapy for Metastatic CAncer of the Lung (RRADICAL)

Anti-PD-L1 in Stage IIIA(N2) Non-small Cell Lung Cancer (NSCLC)

Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475

Erlotinib With or Without Hydroxychloroquine in Chemo-Naive Advanced NSCLC and (EGFR) Mutations

Neoadjuvant Immunoradiation for Resectable Non-Small Cell Lung Cancer

TOP1705

Pathologic and Immunologic Response After Ablative Radiation in Lung Cancer

Chemotherapy and Radiation Therapy With or Without Metformin Hydrochloride in Treating Patients With Stage III Non-small Cell Lung Cancer

SPACEWALK

Calypso-based Deep Inspiration Breath Hold (DIBH) Radiation Treatments of Lung Cancer

SABRseq

Sirolimus and Auranofin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer or Small Cell Lung Cancer

Atezolizumab and Tiragolumab in Patients With NSCLC or Advanced Solid Tumors Having Had Prior Treatment With a PD-1 Inhibitor

Dexamethasone Effects in Patients With Refractory Non-Small Cell Lung Cancer Using FLT Positron Emission Tomography

MEK162